Press Releases – Calliditas Therapeutics AB

Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Nov 20, 2017

Surrogate marker and design of Calliditas Therapeutics’ IgA nephropathy Phase 3 study agreed with the FDA

Nov 15, 2017

Pharmalink is renamed Calliditas Therapeutics

Aug 24, 2017

Thomas Eklund New Chairman of Pharmalink

Aug 15, 2017

Pharmalink strengthens its management team. Appoints new Chief Financial Officer and head of communications

Jul 4, 2017

Positive Phase 2b Trial of Pharmalink’s Nefecon in Primary IgA Nephropathy presented at Leading Kidney Disease Conference

May 31, 2017

Positive Phase 2b Trial of Pharmalink’s Nefecon in IgA Nephropathy Selected for Presentation at Leading Kidney Disease Conference

May 18, 2017

Pharmalink AB announces the appointment of a new Chief Executive Officer

Mar 29, 2017

Positive results of Phase 2b Clinical Trial of Pharmalink’s Nefecon in Primary IgA Nephropathy published in The Lancet